BRCA Testing & Hereditary Breast/Ovarian Cancer

📋 Key Information Summary

📋

Pathogenic variants in BRCA1 and BRCA2 are the most significant hereditary risk factors for breast and ovarian cancer, conferring cumulative lifetime risks of 60–72% (breast) and 11–44% (ovarian) by age 80.
BRCA1 mutations predispose to triple-negative breast cancer (TNBC) and high-grade serous ovarian carcinoma (HGSOC) with earlier onset, while BRCA2 mutations carry a higher lifetime risk of breast cancer but later onset and more oestrogen-receptor–positive tumours.
Testing is indicated for individuals with ≥10% prior probability of carrying a pathogenic BRCA variant using validated risk models (Manchester, Tyrer-Cuzick, BOADICEA), or who meet MBS criteria for Medicare-funded testing.
MBS item 73339 (extended gene panel testing) is available without charge for eligible patients meeting clinical criteria; pre- and post-test genetic counselling is mandatory.
Enhanced surveillance for BRCA carriers includes annual breast MRI from age 25–30 alternating with mammography from age 30–35, and 6-monthly transvaginal ultrasound and CA-125 from age 35.
Risk-reducing bilateral salpingo-oophorectomy (RR-BSO) reduces ovarian cancer mortality by ~80% and is recommended between ages 35–40 (BRCA1) and 40–45 (BRCA2); risk-reducing bilateral mastectomy (RRM) reduces breast cancer risk by >90%.
Olaparib (Lynparza®) and talazoparib (Talzenna®) are PBS-listed PARP inhibitors for germline BRCA-mutated HER2-negative metastatic breast cancer and maintenance therapy in platinum-sensitive recurrent ovarian cancer.
Cascade testing of first- and second-degree relatives is the most cost-effective public health strategy; a positive index result should prompt referral of relatives to a clinical genetics service.
BRCA mutations also confer elevated risk of prostate cancer (BRCA2: 2–6×) and pancreatic cancer; male carriers should be considered for enhanced prostate-specific antigen (PSA) screening from age 40.
Aboriginal and Torres Strait Islander peoples have lower access to genetic services and cascade testing; culturally safe pathways and remote telehealth genetic counselling should be prioritised.
All management decisions in BRCA carriers should be made within a multidisciplinary team (MDT) including medical oncology, surgical oncology, gynaecology, clinical genetics, psychology, and genetic counselling.
Psychological support and informed consent are critical — irreversible decisions such as prophylactic surgery require careful discussion of benefits, harms, body image, fertility, and menopausal implications.

Introduction & Australian Epidemiology

Pathogenic variants in the BRCA1 (chromosome 17q21) and BRCA2 (chromosome 13q12.3) tumour suppressor genes are the most clinically significant inherited predispositions to breast and ovarian cancer. These genes encode proteins essential for homologous recombination repair of double-strand DNA breaks; their inactivation leads to genomic instability and oncogenesis — a phenotype exploited therapeutically by PARP inhibitors.

In Australia, approximately 1 in 300–400 individuals carry a pathogenic BRCA1 or BRCA2 variant, with higher carrier frequencies in certain founder populations. The Australian Institute of Health and Welfare (AIHW) estimates that hereditary breast and ovarian cancer syndrome (HBOC) accounts for 5–10% of all breast cancers and 15–20% of epithelial ovarian cancers diagnosed nationally each year.

The landscape of BRCA testing in Australia has changed markedly since the introduction of Medicare-funded panel-based germline testing (MBS item 73339) in November 2020, removing the previous financial barrier of approximately AUD ,000–,800 per test. This has led to a significant increase in testing rates, earlier identification of carriers, and expanded access to risk-reducing interventions and targeted therapies including olaparib and talazoparib on the Pharmaceutical Benefits Scheme (PBS).

This guideline provides a comprehensive overview of BRCA1/2 testing, cancer risk estimation, evidence-based surveillance protocols, risk-reducing surgical strategies, and the role of PARP inhibitor therapy in the Australian clinical context.

BRCA1 vs BRCA2 Differences

Although both BRCA1 and BRCA2 encode tumour suppressor proteins involved in homologous recombination DNA repair, the two genes differ in their chromosomal location, protein structure, associated cancer spectra, and phenotypic expression. Understanding these differences is essential for risk stratification, screening scheduling, and surgical timing.

Feature	BRCA1	BRCA2
Chromosomal location	17q21	13q12.3
Protein function	RING domain (E3 ubiquitin ligase activity); HR repair; cell-cycle checkpoint	Binds RAD51; HR repair; stabilises stalled replication forks
Breast cancer lifetime risk (to age 80)	72% (95% CI 65–79%)	69% (95% CI 61–77%)
Ovarian cancer lifetime risk (to age 80)	44% (95% CI 36–53%)	17% (95% CI 11–25%)
Peak breast cancer incidence age	40–49 years	50–59 years
Breast cancer histology	Predominantly triple-negative (basal-like, ER−/PR−/HER2−); high grade	More oestrogen-receptor positive (ER+); mixed histology including lobular
Ovarian cancer histology	High-grade serous carcinoma (HGSOC); may arise from fallopian tube	High-grade serous; also mucinous and low-grade subtypes
Contralateral breast cancer (20-year risk)	40–62%	26–52%
Male breast cancer risk	~1–2%	6–8%
Prostate cancer risk	Slightly elevated (~2×)	Significantly elevated (2–6×); aggressive disease
Pancreatic cancer risk	Minimal increased risk	2–4× increased risk (cumulative ~5–7%)
Melanoma	No established association	Possible modest increase
Recommended RRSO age	35–40 years	40–45 years
PARP inhibitor sensitivity	High (synthetic lethality)	High (synthetic lethality)

⚠️

Key clinical distinction: The substantially higher lifetime ovarian cancer risk in BRCA1 carriers (44% vs 17%) justifies earlier risk-reducing salpingo-oophorectomy (ages 35–40 for BRCA1, 40–45 for BRCA2). Delaying RRSO beyond these ages significantly increases the window of risk for a cancer that has limited effective screening.

Penetrance Modifiers

The penetrance of BRCA1/2 mutations is not uniform. Known modifiers include:

Family history: Individuals from families with multiple early-onset breast cancers have higher estimated penetrance than those from families with fewer affected members.
Specific variant location: Variants clustered in the Ovarian Cancer Cluster Region (OCCR) of BRCA2 (exon 11, codons 3059–6629) confer a higher ovarian-to-breast cancer ratio.
Polygenic risk scores: Common low-penetrance alleles (e.g., SNPs identified through genome-wide association studies) can modify BRCA-associated risk 2–3 fold in either direction.
Reproductive factors: Parity, oral contraceptive use, and oophorectomy history modify penetrance (oral contraceptives reduce ovarian cancer risk but may modestly increase breast cancer risk in carriers).

Indications for Testing

BRCA1/2 testing should be offered to individuals who have a ≥10% prior probability of carrying a pathogenic germline variant, or who meet the Medicare Benefits Schedule (MBS) eligibility criteria for funded testing. Testing should always be performed in the context of pre-test genetic counselling provided by an accredited genetic counsellor or clinical geneticist.

MBS Eligibility Criteria (Item 73339)

Medicare-funded extended gene panel testing (including BRCA1, BRCA2, and other hereditary cancer genes) is available for patients who meet any of the following criteria:

Personal history of breast cancer diagnosed at age ≤45 years
Personal history of breast cancer diagnosed at age ≤50 with additional features (bilateral, triple-negative, Ashkenazi Jewish ancestry, male breast cancer, or two or more first/second-degree relatives with breast or ovarian cancer)
Personal history of high-grade serous/fallopian tube/peritoneal carcinoma at any age
Personal history of triple-negative breast cancer diagnosed at age ≤60
Personal history of male breast cancer at any age
A first- or second-degree relative with a known pathogenic variant in a high-risk gene
Two or more first- or second-degree relatives on the same side of the family with breast cancer (at least one diagnosed ≤50) or ovarian cancer at any age
Ashkenazi Jewish ancestry with any personal or family history of breast or ovarian cancer
Personal history of pancreatic cancer with a family history of breast, ovarian, or pancreatic cancer

✅

MBS item 73339: Covers extended gene panel testing at no out-of-pocket cost to the patient when ordered by a specialist (or a GP with specialist referral). This replaced the previous single-gene testing items and enables simultaneous assessment of BRCA1, BRCA2, TP53, PALB2, CHEK2, ATM, and other hereditary cancer genes.

Risk Assessment Models

Several validated models can estimate the prior probability of carrying a BRCA mutation and guide referral for testing:

Model	Inputs	Strengths	Limitations
Manchester Scoring System	Cancer types, ages at diagnosis, family structure	Simple to use; good discrimination; widely used in Australia	May underestimate risk in small families
Tyrer-Cuzick (IBIS) v8	Family history, hormonal factors, BMI, breast density, benign breast disease	Comprehensive; includes non-genetic risk factors; integrates with MRI screening decisions	Complex; requires detailed data
BOADICEA v5	Family history, polygenic risk score, tumour pathology (ER/PR/HER2)	Incorporates polygenic risk; gene-specific estimates; well-validated	Requires specialist software (CanRisk)
BRCAPRO	Bayesian model using family pedigree data	Strong statistical basis; well-calibrated	Sensitive to incomplete family data

Testing Process

BRCA testing in Australia follows a structured pathway:

Referral: GP or specialist refers to an accredited clinical genetics service or familial cancer centre (FCC).
Pre-test counselling: Genetic counsellor assesses family history, discusses implications of testing (psychological, insurance, familial), and obtains informed consent.
Sample collection: Peripheral blood or saliva sample sent to an accredited laboratory (e.g., Peter MacCallum Cancer Centre, Melbourne Genomics, Genetic Health Queensland).
Result and post-test counselling: Typically 2–4 weeks. A positive result triggers discussion of risk management, cascade testing of relatives, and referral to relevant MDTs.
Variant reclassification: Variants of uncertain significance (VUS) are not clinically actionable; families are recalled if a VUS is reclassified to pathogenic or likely pathogenic.

⚠️

Insurance implications: In Australia, moratoriums on genetic discrimination in life insurance were established in 2019 by the Financial Services Council (FSC). For policies ≤0,000 (life), ≤0,000 (total and permanent disability), and other specified thresholds, insurers cannot require or use genetic test results. Patients should be counselled about these protections before testing.

Cancer Risks & Screening Protocols

BRCA1 and BRCA2 carriers face substantially elevated lifetime risks of breast, ovarian, fallopian tube, peritoneal, and other cancers. Risk-estimation, adapted surveillance, and early detection are central pillars of management.

Cumulative Cancer Risks by Age 80

Cancer Site	BRCA1 Lifetime Risk	BRCA2 Lifetime Risk	General Population
Female breast cancer	65–72%	61–69%	~12.5%
Contralateral breast cancer (20-yr post-dx)	40–62%	26–52%	~5–10%
Ovarian/fallopian tube/peritoneal	39–44%	11–17%	~1.2%
Male breast cancer	1–2%	6–8%	0.1%
Prostate cancer	Slightly elevated	20–30% (aggressive)	~12% lifetime
Pancreatic cancer	1–2%	5–7%	~1.5%

Breast Cancer Screening — BRCA1/2 Carriers

Standard population mammographic screening (BreastScreen Australia, biennial from age 50) is insufficient for BRCA carriers. Enhanced protocols are recommended by Cancer Australia and the Royal Australian College of Radiologists (RACR):

Age 18–24

Breast awareness education
Monthly self-examination; clinical breast examination (CBE) every 6–12 months by a healthcare provider. MRI not routinely recommended before age 25 unless a family member was diagnosed under 25.

Age 25–29

Annual breast MRI (with contrast; MBS rebate available for high-risk screening). Mammography not routinely recommended due to breast density in younger women and cumulative radiation concerns.

Age 30–49

Annual breast MRI alternating with annual mammography (i.e., MRI one year, mammography the next — 6-monthly interval screening). Consider adding breast ultrasound if mammographic density is high.

Age 50+

Continue annual screening with MRI and/or mammography. If RRM has been performed, clinical surveillance of chest wall and remaining breast tissue may still be appropriate. Surveillance continues lifelong unless RRM performed bilaterally.

ℹ️

MBS breast MRI: MRI breast screening is covered under MBS items for women with a cumulative lifetime risk of ≥20%, which includes all confirmed BRCA1/2 carriers. Referral from a specialist (surgeon, oncologist, or clinical geneticist) is required.

Ovarian Cancer Screening — BRCA1/2 Carriers

No screening modality has been proven to reduce ovarian cancer mortality. Nonetheless, surveillance is offered to carriers who decline or defer risk-reducing salpingo-oophorectomy:

Transvaginal ultrasound (TVUS): Every 6–12 months from age 30–35 (BRCA1) or 35–40 (BRCA2). Sensitivity for early-stage disease remains limited.
Serum CA-125: Every 6 months in conjunction with TVUS. Reference change value (RCV) methodology improves sensitivity over absolute thresholds. Elevated levels warrant urgent gynaecological-oncology referral.
Risk of Ovarian Cancer Algorithm (ROCA): Uses serial CA-125 measurements to detect trends; not widely available in routine Australian practice but has been studied in the UK UKFOCSS and GOG-0199 trials.

🚨

Critical caveat: Screening with TVUS and CA-125 has not been shown to reduce ovarian cancer mortality. The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) found no survival benefit with multimodal screening in the general population. RRSO remains the only evidence-based strategy to reduce ovarian cancer risk in BRCA carriers.

Other Cancer Screening

Prostate cancer (male BRCA2 carriers): PSA-based screening from age 40, every 1–2 years; consider MRI prostate for elevated PSA. Refer Cancer Council Australia and Prostate Cancer Foundation of Australia guidelines.
Pancreatic cancer (BRCA2): No established screening protocol in Australia; consider endoscopic ultrasound (EUS) and/or MRI/MRCP annually from age 50 if combined with a family history of pancreatic cancer (refer to international CAPS consortium criteria).
Skin cancer: Standard Australian surveillance (regular skin checks) — BRCA2 carriers may have modestly increased melanoma risk.

Risk-Reducing Interventions (Surgery & PARP Inhibitors)

Risk-reducing surgery and targeted pharmacological therapy form the cornerstone of cancer prevention and treatment in BRCA1/2 carriers. All decisions should be individualised within a multidisciplinary team framework, incorporating patient preference, reproductive plans, menopausal status, and psychological readiness.

Risk-Reducing Bilateral Salpingo-Oophorectomy (RR-BSO)

✅

Strongest evidence-based intervention for ovarian cancer risk reduction. RR-BSO reduces ovarian, fallopian tube, and primary peritoneal cancer risk by ~80% and all-cause mortality by ~77% in BRCA1 carriers (Domchek et al., JAMA 2010). Recommended by Cancer Australia, ESMO, NCCN, and SGO.

Parameter	BRCA1	BRCA2
Recommended age for RR-BSO	35–40 years	40–45 years
Surgical approach	Laparoscopic (preferred); complete removal of ovaries, fallopian tubes, and fimbriae; thorough peritoneal washings for cytology
Pathological assessment	SEE-FIM protocol (Sectioning and Extensively Examining the Fimbriated end) — serial sectioning of fimbriae at 2 mm intervals to detect occult serous tubal intraepithelial carcinoma (STIC)
Breast cancer risk reduction	~50% reduction in premenopausal carriers	~50% reduction in premenopausal carriers
Residual peritoneal cancer risk	~1–4% lifetime (primary peritoneal carcinoma)	~1–4% lifetime
Consequences	Immediate surgical menopause; increased cardiovascular, bone, and cognitive risk; vasomotor symptoms. Discuss HRT (oestrogen-only if hysterectomy performed; combined if uterus retained) — generally considered safe for short-term use if no breast cancer history.

Opportunistic Salpingectomy (OS) with Delayed Oophorectomy

Emerging evidence from the TUBA study (Netherlands) and the SOROCk trial supports bilateral salpingectomy alone at age 35–40 with delayed oophorectomy at natural menopause age (~50) as an option for BRCA carriers who wish to avoid premature surgical menopause. This approach is not yet standard of care in Australia and should be discussed within an MDT with acknowledgement of limited long-term oncological outcome data.

⚠️

Experimental approach: Risk-reducing salpingectomy with delayed oophorectomy is considered investigational. Patients choosing this pathway should be enrolled in a clinical trial or prospective registry (e.g., the Australian and New Zealand Gynaecological Oncology Group [ANZGOG] studies) where available.

Risk-Reducing Mastectomy (RRM)

Risk-reducing mastectomy (bilateral or contralateral) reduces breast cancer risk by >90% in BRCA carriers and is associated with a significant reduction in breast cancer-specific mortality. However, it is an irreversible, body-altering procedure and requires thorough multidisciplinary discussion.

Option

Bilateral Risk-Reducing Mastectomy (BRRM)

Removal of >95% of breast tissue bilaterally. Breast reconstruction (immediate or delayed) is offered concurrently. Reduces breast cancer risk by >90%.

Setting: Specialist breast surgery centre; requires plastic surgery for reconstruction

Option

Contralateral Risk-Reducing Mastectomy (CRRM)

For carriers already diagnosed with unilateral breast cancer. Removes the unaffected breast. Reduces contralateral cancer risk by >95%. Does not definitively improve overall survival (vs. enhanced surveillance) but may reduce anxiety.

Setting: Discussed at breast MDT; timing relative to adjuvant therapy important

Consideration

Enhanced Surveillance (Alternative to RRM)

Annual MRI + mammography (as per screening protocol). Many carriers choose surveillance over surgery. Equivalent survival outcomes demonstrated for carriers who are regularly screened and treated promptly if cancer develops.

Setting: Familial cancer clinic; long-term compliance with screening essential

PARP Inhibitors

Poly(ADP-ribose) polymerase (PARP) inhibitors exploit the concept of synthetic lethality: BRCA-deficient cells cannot repair DNA double-strand breaks by homologous recombination, and PARP inhibition further impairs single-strand break repair, leading to cell death. Two PARP inhibitors are PBS-listed in Australia:

💊

Olaparib

Lynparza® · AstraZeneca · PARP inhibitor

Indications (PBS) HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2 mutation (previously treated with chemotherapy); maintenance therapy in platinum-sensitive relapsed high-grade serous ovarian cancer with germline BRCA1/2 mutation (post platinum-based chemotherapy)

Adult dose (breast) 300 mg PO BD continuously until disease progression or unacceptable toxicity

Adult dose (ovarian maintenance) 300 mg PO BD (tablets) or 400 mg PO BD (capsules) until disease progression

Key AEs Nausea (most common), fatigue, anaemia, neutropenia, thrombocytopenia; rare MDS/AML (≤2%)

Monitoring FBC every month for 1st year, then periodically; renal function (CrCl)

Renal adjustment CrCl 31–50 mL/min: 200 mg BD (tablets) or 300 mg BD (capsules); avoid if CrCl ≤31 mL/min

PBS status ⚠ PBS Authority Required

💊

Talazoparib

Talzenna® · Pfizer · PARP inhibitor

Indications (PBS) HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2 mutation (previously treated with chemotherapy, including a taxane and/or anthracycline)

Adult dose 1 mg PO once daily (dose reduction to 0.75 mg or 0.5 mg for haematological toxicity or renal impairment)

Key AEs Anaemia (most common dose-limiting AE), fatigue, nausea, neutropenia, thrombocytopenia

Renal adjustment CrCl 30–59 mL/min: 0.75 mg daily; avoid if CrCl <30 mL/min

PBS status ⚠ PBS Authority Required

PBS Authority Criteria — PARP Inhibitors

PBS-subsidised olaparib and talazoparib require Authority approval and are available when:

A germline pathogenic BRCA1 or BRCA2 mutation has been confirmed by a validated test in a NATA/RCPA-accredited laboratory.
For breast cancer: the patient has HER2-negative locally advanced or metastatic disease and has received prior chemotherapy (including an anthracycline and taxane, unless contraindicated).
For ovarian cancer: olaparib maintenance following complete or partial response to platinum-based chemotherapy for recurrent HGSOC.
The prescribing specialist has authority from Services Australia (Department of Human Services).

⚠️

Haematological toxicity: Myelosuppression is the most common serious adverse effect of PARP inhibitors. FBC should be performed monthly during the first 12 months. Dose interruption and reduction protocols must be followed per TGA-approved Product Information. Patients should be counselled about signs of infection (neutropenia) and bleeding (thrombocytopenia).

Other Targeted Therapies

Platinum-based chemotherapy: BRCA-mutated tumours (particularly ovarian and TNBC) are exquisitely sensitive to platinum agents (carboplatin, cisplatin). Carboplatin is the backbone of first-line and relapsed ovarian cancer therapy.
Immunotherapy: BRCA1-associated TNBC often has high tumour-infiltrating lymphocyte (TIL) counts and PD-L1 expression, making these tumours candidates for checkpoint inhibitors (e.g., pembrolizumab + chemotherapy in triple-negative breast cancer — PBS-listed).
Antibody-drug conjugates: Sacituzumab govitecan (Trodelvy®) is TGA-approved and PBS-listed for metastatic TNBC, relevant for BRCA1-mutated disease.

Special Populations

🤰 Pregnancy & Fertility

Preimplantation genetic testing (PGT-M): Available at accredited IVF centres for carriers wishing to avoid transmission. Medicare rebate for PGT-M may apply under specific criteria (Reproductive Technology Accreditation Committee [RTAC] clinics).

Timing of RRSO: Should be deferred until childbearing is complete for BRCA1 carriers choosing RRSO at ages 35–40; fertility preservation (oocyte or embryo cryopreservation) should be discussed before any risk-reducing surgery.

Contraception: Oral combined oral contraceptive pill (COCP) reduces ovarian cancer risk by ~50% with ≥5 years of use but may modestly increase breast cancer risk. Mirena IUD (levonorgestrel) may be preferred for contraception without systemic oestrogen exposure.

Pregnancy: BRCA mutation status does not alter obstetric management. Breast surveillance (clinical examination) is performed as per trimester; MRI is avoided in the first trimester but may be used in the second/third trimester if clinically indicated.

👶 Paediatric & Adolescent Carriers

Testing age: Genetic testing is generally deferred until age 18 (or when the young person has capacity for informed consent) as BRCA-associated cancers are exceptionally rare in childhood/adolescence. Exceptions include families with TP53 co-mutations (Li-Fraumeni).

Cascade testing: Young adults (18–25) who test positive should begin breast awareness education and clinical breast examination every 6–12 months. Enhanced imaging screening begins at age 25.

Psychological support: Adolescent carriers may experience significant anxiety about future cancer risk; referral to a psychologist experienced in hereditary cancer syndromes is recommended.

👴 Elderly Carriers (≥70 years)

Cancer risk remains elevated: Lifetime risk does not plateau; continued surveillance is recommended unless limited life expectancy or patient preference.

Surgical decisions: RRSO benefit diminishes after age 65–70 due to reduced residual ovarian cancer risk; decision should balance surgical risk vs. benefit in the context of comorbidities.

PARP inhibitor tolerability: Elderly patients may be more susceptible to myelosuppression; closer FBC monitoring and earlier dose reduction may be warranted.

🫘 Renal Impairment

Olaparib: Reduce dose for CrCl 31–50 mL/min; avoid if CrCl ≤31 mL/min.

Talazoparib: Reduce to 0.75 mg daily for CrCl 30–59 mL/min; avoid if CrCl <30 mL/min.

Carboplatin: Dose by Calvert formula (AUC-based); requires accurate eGFR.

🫁 Hepatic Impairment

Olaparib: Mild hepatic impairment (Child-Pugh A): no dose adjustment; moderate-severe: use with caution, limited data.

Talazoparib: No dose adjustment for mild-moderate hepatic impairment; limited data in severe impairment.

🛡️ Immunocompromised Carriers

PARP inhibitors & myelosuppression: Baseline immunocompromise (e.g., HIV, organ transplant) increases risk of haematological toxicity; enhanced monitoring required.

Infection risk: Patients on olaparib or talazoparib should be counselled about neutropenic sepsis signs and have a low threshold for empirical antibiotics when febrile.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples face significant disparities in access to genetic testing, cancer screening, and risk-reducing interventions for hereditary breast and ovarian cancer. These inequities contribute to later-stage diagnoses and poorer outcomes.

Key Disparities

Access to genetic services

Fewer familial cancer centres and genetic counsellors in rural and remote Australia. Many Indigenous Australians have never been offered genetic testing despite meeting eligibility criteria. Telehealth genetic counselling (via platforms such as Genetic Health Queensland or Victorian Clinical Genetics Services) can partially bridge this gap.

Cascade testing uptake

Cascade testing rates among ATSI relatives of known carriers are significantly lower than non-Indigenous Australians. Barriers include geographic isolation, distrust of health systems, cultural unfamiliarity with Western genetic concepts, and lack of culturally appropriate educational resources.

Screening participation

ATSI women have lower participation in BreastScreen Australia and reduced access to breast MRI. Remote communities may lack imaging facilities, requiring travel of hundreds of kilometres.

Surgical access

Risk-reducing surgery (RRSO, RRM) requires referral to a tertiary centre with gynaecological-oncology or breast surgery capabilities. ATSI patients in remote areas face logistical barriers (travel, accommodation, cultural disconnection from country and community).

Cultural safety

Genetic testing and prophylactic surgery require nuanced discussion of kinship, body image, reproductive autonomy, and intergenerational responsibility. Culturally safe genetic counselling involves Aboriginal Health Workers (AHWs), Aboriginal Liaison Officers (ALOs), and acknowledgement of community decision-making norms. Yarning-based approaches may be more effective than structured Western counselling models.

Data sovereignty

ATSI communities have legitimate concerns about the collection, storage, and use of genetic data. The Australian Genomics Health Alliance (AGHA) and the National Centre for Indigenous Genomics (NCIG) have developed governance frameworks that respect Indigenous data sovereignty principles.

Recommendations for Clinicians

Actively enquire about family cancer history in ATSI patients and refer for genetic counselling if criteria are met — do not assume disinterest or inability to access services.
Engage Aboriginal Health Workers (AHWs) and Aboriginal Medical Services (AMS) in the referral, counselling, and follow-up process.
Use telehealth for pre- and post-test genetic counselling where in-person attendance is impractical; ensure culturally appropriate materials are provided.
Support navigation services to assist ATSI patients in accessing surgery, imaging, and PBS-listed PARP inhibitors.
Advocate for increased funding for hereditary cancer services in rural and remote Australia, including subsidised travel for RRSO and enhanced screening.

📚 References

1. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–2416.
2. Cancer Australia. Clinical practice guidelines for the management of breast cancer. Surry Hills, NSW: Cancer Australia; 2024. Available from: cancer.gov.au.
3. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–975.
4. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533.
5. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–763.
6. National Health and Medical Research Council (NHMRC). Additional decision-making principles for the management of Aboriginal and Torres Strait Islander peoples. Canberra: NHMRC; 2020.
7. Australian Institute of Health and Welfare (AIHW). Cancer in Australia 2024. Cancer series no. 140. Canberra: AIHW; 2024.
8. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055–1062.
9. Australian Government Department of Health. Medicare Benefits Schedule — Item 73339 (Extended genomic testing). Canberra: Services Australia; 2024.
10. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945–956.
11. Eccles DM, Mitchell G, Monteiro ANA, et al. BRCA1 and BRCA2 genetic testing — pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol. 2015;26(10):2057–2065.
12. Tischkowitz M, Huang S, Banerjee S, et al. Small-cell carcinoma of the ovary, hypercalcemic type — genetics, genomics, and the road ahead. Gynecol Oncol. 2020;159(3):581–587.
13. National Comprehensive Cancer Network (NCCN). Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic — Version 2.2024. Plymouth Meeting, PA: NCCN; 2024.
14. Steuten L, Pyle L, Engel N, et al. Cost-effectiveness of PARP inhibitors in germline BRCA-mutated metastatic breast cancer: a systematic review. Pharmacoeconomics. 2022;40(7):657–672.